Loading…
Loading…
Under normal market conditions, the fund seeks to meet its investment objective by investing in large- and mid-cap equity securities, including common stocks, related depository receipts, real estate investment trusts (“REITs”), and other equity investments or ownership interests in business enterprises. It invests predominantly in common stocks of large- and mid-cap companies (the “Investable Universe”). The fund’s derivative investments may include, among other instruments: (i) options; (ii) volatility-linked ETFs; and (iii) volatility-linked exchange-traded notes (“ETNs”). It is non-diversified.
Is KONG's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Tokyo, Japan, March 31, 2026 (GLOBE NEWSWIRE) -- Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today announced that it has entered into a master agreement for the sale and purchase of goods (the “Agreement”) with TASLY (HONG KONG) INTERNATIONAL HOLDING COMPANY LIMITED (“TASLYHONG KONG”), a Hong Kong-based trading company, for the distribution of its health products, cosmetics and liquors.
HONG KONG, April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical Products Administration (NMPA) for its supplementary New Drug Application (sNDA) for use as a monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) in patients who are negative for epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) gene mutations. This indication marks Ivonescimab's second major approval. The sNDA approval is based on the breakthrough results of the AK112-303/HARMONi-2 Phase III study, which is a randomized, double-blind, controlled study that directly compared ivonescimab with pembrolizumab in first line PD-L1 positive NSCLC. Ivonescimab is the first bispecific antibody approved globally with a dual "cancer immunotherapy + anti-angiogenesis" mechanism. It has already shown significant positive results in three Phase III trials for lung cancer, including 1) treatment for EGFR-TKI-resistant NSCLC, 2) comparison with pembrolizumab in PD-L1-positive NSCLC, and 3) treatment in combination with chemotherapy versus tislelizumab in combination with chemotherapy in squamous NSCLC. Professor Zhou Caicun, principal investigator of the HARMONi-2 trial, director of the Department of Oncology at the Shanghai East Hospital, Tongji University, commented: "The Phase III HARMONi-2 study demonstrated that ivonescimab offers significant improvements in progression-free survival (PFS) and overall survival (OS) compared to pembrolizumab. This breakthrough provides a safer and more effective first-line treatment option for NSCLC, particularly beneficial for patients who need better efficacy or quality of life, or those who are not suitable for chemotherapy due to its side effects. Ivonescimab has also gained widespread recognition in treating EGFR-TKI-resistant NSCLC. The recent Phase III trial combining ivonescimab with chemotherapy, compared to tislelizumab for squamous NSCLC, showed promising positive results. Ivonescimab is now positioned as a new standard of care for both first- and second-line treatment in lung cancer. We are optimistic about its continued success in global Phase III trials and its potential to redefine cancer treatment standards worldwide." Dr. Xia Yu, Founder, Chairwoman, President, and CEO of Akeso, commented: "We are thrilled to announce the approval of ivonescimab as a first-line treatment for PD-L1-positive NSCLC, a major breakthrough in cancer immunotherapy. This milestone is a result of the dedication of investigators, participants, and patients, and we sincerely thank all of them. We also appreciate the regulatory authorities for their efficient and diligent review, which enables us to offer this new treatment to patients in China. Ivonescimab has shown superior efficacy over pembrolizumab in the HARMONi-2 Phase III trial, becoming the first therapy to achieve this globally. Positive results so far from three pivotal Phase III lung cancer trials further establish ivonescimab as a next-gen IO treatment with strong global potential. The clinical data highlights ivonescimab's exceptional efficacy and safety benefits for patients across various cancer types. Beyond lung, ivonescimab has demonstrated promising potential as first-line treatment for other key cancers, including breast, head and neck, biliary tract, and colorectal cancer, supported by, over 12 ongoing Phase III trials. Akeso, along with our partner Summit, are committed to advancing ivonescimab as a cornerstone of global cancer immunotherapy, aiming to provide safer, more effective treatment options for patients worldwide." About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 4 new drugs with 4 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
Von einem ruhigen Abend bis hin zu lebendigen Gartenpartys bietet Govees neue Außenleuchte die Atmosphäre und Funktionalität für das perfekte Sommer Ambiente HONG KONG, 20. Mai 2024 /PRNewswire/ -- Govee, ein weltweit bekannter Hersteller für Smart-Home-Lösungen, gibt heute die Verfügbarkeit neuer Ergänzung zu seinen Produktserien von Außenleuchten bekannt: Die Govee Außenwandleuchte. Ob Sie während der Sommermonate eine Party mit den Familien und Freunden feiern oder einen ruhigen Abend alleine genießen möchten, bietet sich diese intelligente Außenwandleuchte an, die nicht nur für Beleuchtung, sondern auch für Romantik sorgt, wodurch sich das Leben im Außenbereich verbessert. Das ultimative Upgrade für Ihr Außen-Erlebnis In einem Markt, der größtenteils von einfachen, nicht-smarten und nicht-RGB-fähigen Außenwandleuchten dominiert wird, setzt Govee mit seiner Smart RGBICWW Außenwandleuchte einen neuen Standard. Diese fortschrittliche Beleuchtungslösung behebt die häufigen Probleme unzureichender Beleuchtung und begrenzter Anpassungsmöglichkeiten, die die herkömmliche Außenbeleuchtung beeinträchtigen. Mit innovativen Funktionen, die auf den modernen Hausbesitzer zugeschnitten sind, bietet die Außenwandbeleuchtung von Govee ein umfassendes Upgrade, um jeden Außenbereich zu verbessern: Verfügbarkeit Die Govee Außenwandleuchte ist jetzt bei Govee.com und Amazon für UVP 89,99€ (1er-Set) und 169,99€ (2er-Set) verfügbar. Über Govee Seit 2017 setzt sich Govee dafür ein, das Leben intelligenter zu machen und ein besseres Kundenerlebnis in allen Szenarien zu schaffen. Als ein weltweit bekannter Hersteller für Smart-Home-Lösungen setzt sich das Unternehmen zum Ziel, durch kontinuierliche Innovationen im Smart-Home-Bereich personalisierte und unterhaltsame Lebenserfahrungen zu bieten, wobei der Schwerpunkt auf Beleuchtungslösungen und Haushaltsgeräten liegt. Weitere Informationen zu Govee finden Sie auf unserer Website govee.com. Foto - https://mma.prnewswire.com/media/2416675/image_5010931_9906638.jpg
For the details of NEW THINKING (HONG KONG) INVESTMENT MANAGEMENT CO. Ltd's stock buys and sells, go to https://www.gurufocus.com/guru/new+thinking+%28hong+kong%29+investment+management+co.